Evogene (EVGN) Change in Interest Receivables (2020 - 2022)
Evogene (EVGN) posted Change in Interest Receivables of $7000.0 for Q1 2022, up 275.0% sequentially from -$4000.0 in Q4 2021, and down 41.67% YoY from $12000.0 in Q1 2021.
Evogene (EVGN) Change in Interest Receivables (2020 - 2022) Analysis & Trends
Evogene has reported Change in Interest Receivables for 3 years, with the latest figure at $7000.0 in Q1 2022.
- Quarterly Change in Interest Receivables fell 41.67% year-over-year to $7000.0 in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $7000.0 (up 600.0% YoY) and the FY2022 annual result came in at $7000.0, down 36.36% from the prior year.
- Change in Interest Receivables climbed to $7000.0 in Q1 2022 per EVGN's latest filing, from -$4000.0 in the prior quarter.
- Over five years, Change in Interest Receivables peaked at $27000.0 in Q4 2020 and troughed at -$12000.0 in Q2 2021.
- A 3-year average of $8571.4 and a median of $7000.0 in 2022 frame the typical range for Change in Interest Receivables.
- The sharpest annual moves came in 2021 and 2022: Change in Interest Receivables sank 114.81% in 2021, then sank 41.67% in 2022.
- Over 3 years, Change in Interest Receivables stood at $27000.0 in 2020, then tumbled by 114.81% to -$4000.0 in 2021, then surged by 275.0% to $7000.0 in 2022.
- According to Business Quant data, Change in Interest Receivables over the past three periods registered $7000.0, -$4000.0, and $5000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Sep 30, 2021 | 5,000.00 |
| Jun 30, 2021 | -12,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 27,000.00 |
| Mar 31, 2020 | 25,000.00 |